Author:
Dokoupilová Eva,Vetchý David,Pavloková Sylvie,Hanuštiaková Markéta
Reference49 articles.
1. Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis;Alten;Int. J. Rheumatic Dis. [online].,2020
2. Hepatitis a vaccine for immunosuppressed patients with rheumatoid arthritis: a prospective, open-label, multi-Centre study;Askling;Travel Med. Infect. Dis. [online],2014
3. Adalimumab and infliximab impair SARS-CoV-2 antibody responses: results from a therapeutic drug monitoring study in 11422 biologic-treated patients;Chanchlani;J. Crohns Colitis,2022
4. Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor-α inhibitors;Chen;Med. [online],2021
5. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study;Cohen;Ann. Rheum. Dis.,2017